Loprevite M - Search Results

1

Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.

Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A. Loprevite M, et al. Clin Cancer Res. 2007 Nov 1;13(21):6518-26. doi: 10.1158/1078-0432.CCR-07-0805. Clin Cancer Res. 2007. PMID: 17975165

2

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.

Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A. Tiseo M, et al. Among authors: loprevite m. J Thorac Oncol. 2008 Oct;3(10):1104-11. doi: 10.1097/JTO.0b013e3181861d67. J Thorac Oncol. 2008. PMID: 18827605 Free article.

3

Histone deacetylation inhibitors.

Ardizzoni A, Loprevite M. Ardizzoni A, et al. Among authors: loprevite m. Suppl Tumori. 2002 Jul-Aug;1(4):S52-4. Suppl Tumori. 2002. PMID: 12415821 Review. No abstract available.

4

In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A. Loprevite M, et al. Oncol Res. 2005;15(1):39-48. doi: 10.3727/096504005775082066. Oncol Res. 2005. PMID: 15839304

5

Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.

Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Tiseo M, et al. Among authors: loprevite m. Anticancer Res. 2008 Jan-Feb;28(1B):507-13. Anticancer Res. 2008. PMID: 18383893 Free article.

6

The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer.

Grossi F, Scolaro T, Tixi L, Loprevite M, Ardizzoni A. Grossi F, et al. Among authors: loprevite m. Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7. doi: 10.1016/s1040-8428(00)00098-6. Crit Rev Oncol Hematol. 2001. PMID: 11164720 Review.

7

Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines.

Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, Bruno S, Grossi F, Scolaro T, Ardizzoni A. Loprevite M, et al. Lung Cancer. 2001 Jul;33(1):27-39. doi: 10.1016/s0169-5002(00)00247-6. Lung Cancer. 2001. PMID: 11429193

8

Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.

Grossi F, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L, Ardizzoni A. Grossi F, et al. Among authors: loprevite m. Eur J Cancer. 2003 Jun;39(9):1242-50. doi: 10.1016/s0959-8049(03)00232-6. Eur J Cancer. 2003. PMID: 12763212

9

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

Tiseo M, Loprevite M, Ardizzoni A. Tiseo M, et al. Among authors: loprevite m. Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. doi: 10.2174/1568011043482106. Curr Med Chem Anticancer Agents. 2004. PMID: 15032719 Review.

10

In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.

Loprevite M, Favoni RE, De Cupis A, Scolaro T, Semino C, Mazzanti P, Ardizzoni A. Loprevite M, et al. Oncol Rep. 2004 Feb;11(2):407-14. Oncol Rep. 2004. PMID: 14719076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters